Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1546–1553. doi: 10.1128/aac.39.7.1546

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults.

K R Beutner 1, D J Friedman 1, C Forszpaniak 1, P L Andersen 1, M J Wood 1
PMCID: PMC162779  PMID: 7492102

Abstract

Acyclovir treatment of acute herpes zoster speeds rash healing and decreases pain and ocular complications. The limited oral bioavailability of acyclovir necessitates frequent dosing. Valaciclovir, the l-valyl ester of acyclovir, is rapidly and almost completely converted to acyclovir in vivo and gives three- to fivefold increases in acyclovir bioavailability. In a randomized, double-blind, multicenter study, the safety and efficacy of oral valaciclovir given at a dosage of 1,000 mg three times daily for 7 or 14 days and oral acyclovir given at a dosage of 800 mg five times daily for 7 days were compared in immunocompetent adults aged > or = 50 years with herpes zoster. Patients were evaluated for 6 months. The intent-to-treat analysis (1,141 patients) showed that valaciclovir for 7 or 14 days significantly accelerated the resolution of herpes zoster-associated pain (P = 0.001 and P = 0.03, respectively) compared with acyclovir; median pain durations were 38 and 44 days, respectively, versus 51 days for acyclovir. Treatment with valaciclovir also significantly reduced the duration of postherpetic neuralgia and decreased the proportion of patients with pain persisting for 6 months (19.3 versus 25.7%). However, there were no differences between treatments in pain intensity or quality-of-life measures. Cutaneous manifestations resolved at similar rates in all groups. Adverse events were similar in nature and prevalence among groups, and no clinically important changes occurred in hematology or clinical chemistry parameters. Thus, in the management of immunocompetent patients > or = 50 years of age with localized herpes zoster, valaciclovir given at 1,000 mg three times daily for 7 days accelerates the resolution of pain and offers simpler dosing, while it maintains the favorable safety profile of acyclovir.

Full Text

The Full Text of this article is available as a PDF (223.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BURGOON C. F., Jr, BURGOON J. S., BALDRIDGE G. D. The natural history of herpes zoster. J Am Med Assoc. 1957 May 18;164(3):265–269. doi: 10.1001/jama.1957.02980030041010. [DOI] [PubMed] [Google Scholar]
  2. Burke B. L., Steele R. W., Beard O. W., Wood J. S., Cain T. D., Marmer D. J. Immune responses to varicella-zoster in the aged. Arch Intern Med. 1982 Feb;142(2):291–293. [PubMed] [Google Scholar]
  3. Cobo L. M., Foulks G. N., Liesegang T., Lass J., Sutphin J. E., Wilhelmus K., Jones D. B., Chapman S., Segreti A. C., King D. H. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986 Jun;93(6):763–770. doi: 10.1016/s0161-6420(86)33678-9. [DOI] [PubMed] [Google Scholar]
  4. Cole N. L., Balfour H. H., Jr Varicella-Zoster virus does not become more resistant to acyclovir during therapy. J Infect Dis. 1986 Mar;153(3):605–608. doi: 10.1093/infdis/153.3.605. [DOI] [PubMed] [Google Scholar]
  5. Crooks R. J., Jones D. A., Fiddian A. P. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl. 1991;80:62–68. [PubMed] [Google Scholar]
  6. DE MORAGAS J. M., KIERLAND R. R. The outcome of patients with herpes zoster. AMA Arch Derm. 1957 Feb;75(2):193–196. doi: 10.1001/archderm.1957.01550140037006. [DOI] [PubMed] [Google Scholar]
  7. Gracely R. H., Dubner R., McGrath P. A. Narcotic analgesia: fentanyl reduces the intensity but not the unpleasantness of painful tooth pulp sensations. Science. 1979 Mar 23;203(4386):1261–1263. doi: 10.1126/science.424753. [DOI] [PubMed] [Google Scholar]
  8. HOPE-SIMPSON R. E. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med. 1965 Jan;58:9–20. doi: 10.1177/003591576505800106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harding S. P., Porter S. M. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res. 1991;10 (Suppl):177–182. doi: 10.3109/02713689109020376. [DOI] [PubMed] [Google Scholar]
  10. Hope-Simpson R. E. Postherpetic neuralgia. J R Coll Gen Pract. 1975 Aug;25(157):571–575. [PMC free article] [PubMed] [Google Scholar]
  11. Huff J. C., Bean B., Balfour H. H., Jr, Laskin O. L., Connor J. D., Corey L., Bryson Y. J., McGuirt P. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988 Aug 29;85(2A):84–89. [PubMed] [Google Scholar]
  12. Huff J. C., Drucker J. L., Clemmer A., Laskin O. L., Connor J. D., Bryson Y. J., Balfour H. H., Jr Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol. 1993;Suppl 1:93–96. doi: 10.1002/jmv.1890410518. [DOI] [PubMed] [Google Scholar]
  13. Loeser J. D. Herpes zoster and postherpetic neuralgia. Pain. 1986 May;25(2):149–164. doi: 10.1016/0304-3959(86)90089-8. [DOI] [PubMed] [Google Scholar]
  14. Morton P., Thomson A. N. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J. 1989 Mar 8;102(863):93–95. [PubMed] [Google Scholar]
  15. Ragozzino M. W., Melton L. J., 3rd, Kurland L. T., Chu C. P., Perry H. O. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982 Sep;61(5):310–316. doi: 10.1097/00005792-198209000-00003. [DOI] [PubMed] [Google Scholar]
  16. Riopelle J. M., Naraghi M., Grush K. P. Chronic neuralgia incidence following local anesthetic therapy for herpes zoster. Arch Dermatol. 1984 Jun;120(6):747–750. [PubMed] [Google Scholar]
  17. Tilson H. H., Engle C. R., Andrews E. B. Safety of acyclovir: a summary of the first 10 years experience. J Med Virol. 1993;Suppl 1:67–73. doi: 10.1002/jmv.1890410513. [DOI] [PubMed] [Google Scholar]
  18. Weller S., Blum M. R., Doucette M., Burnette T., Cederberg D. M., de Miranda P., Smiley M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595–605. doi: 10.1038/clpt.1993.196. [DOI] [PubMed] [Google Scholar]
  19. Whitley R. J., Gnann J. W., Jr Acyclovir: a decade later. N Engl J Med. 1992 Sep 10;327(11):782–789. doi: 10.1056/NEJM199209103271108. [DOI] [PubMed] [Google Scholar]
  20. Whitley R. J. Therapeutic approaches to varicella-zoster virus infections. J Infect Dis. 1992 Aug;166 (Suppl 1):S51–S57. doi: 10.1093/infdis/166.supplement_1.s51. [DOI] [PubMed] [Google Scholar]
  21. Wood M. J., Johnson R. W., McKendrick M. W., Taylor J., Mandal B. K., Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994 Mar 31;330(13):896–900. doi: 10.1056/NEJM199403313301304. [DOI] [PubMed] [Google Scholar]
  22. Wood M. J., Ogan P. H., McKendrick M. W., Care C. D., McGill J. I., Webb E. M. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med. 1988 Aug 29;85(2A):79–83. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES